Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790548 | 0.92 | PTGS2 (0.41) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL15255483 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL1791081 | 0.90 | TP53 (0.41) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL5109646 | 0.88 | NTRK1 (0.42) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL1791038 | 0.88 | PTGS2 (0.38) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL5112341 | 0.88 | PTGS2 (0.48) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL1789966 | 0.86 | PTGS2 (0.39) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL1791837 | 0.85 | MAPT (0.37) | PTGS2PTGS1TP53SMN1; SMN2MAPT | |
| SCHEMBL1790566 | 0.85 | SOS1 (0.37) | PTGS2PTGS1ADORA2A | |
| SCHEMBL12651767 | 0.84 | PTGS2 (0.35) | PTGS2MAPTPIN1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | claimed |
| WO-2010002998-A1 | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | PTGS2 491/4885PTGS1 598/4885TP53 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.